MedTrace Logo

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

NCT03993132 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26774

Last updated 2024-02-12

Study results available
· View outcomes & findings →

Summary

The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin

new users (initiators) of Empagliflozin

DRUG

Liraglutide

initiators of Liraglutide

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2022-06-16
Completion
2022-06-16

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03993132 on ClinicalTrials.gov